UBX: Rega marang dodolan Unity Biotechnology Inc.
Patents for senolytic methods create a significant defensive moat for Unity Biotechnology (UBX). The P/S multiple illustrates the market response to these advantages. The company is implementing IT simulations to combat aging, although R&D cash burn and the risk of trial volatility are creating pressure. Meanwhile, the 184.40 level captures the current real-time valuation of the business.
Rincian metrik lan analitis perusahaan Unity Bio (UBX)
- kuotasi lan prakiraan analis:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas Unity Biotechnology|UBX - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang modal Unity Biotechnology, Inc|UBX - Utang perusahaan|Rasio utang marang kapitalisasi buku Unity Bio|UBX - Utang jangka dawa perusahaan|Utang jangka cendhak Unity Biotechnology|Likuiditas kritis unitybiotechnology.com
- data bathi bisnis lan rasio investasi:
UBX - Penghasilan resik|Bathi resik sing dikarepake Unity Biotechnology|UBX - Koefisien rega marang bathi|Pangali Forward P/E Unity Biotechnology Inc.|UBX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Unity Bio|UBX - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone 12 wulan pungkasan Unity Biotechnology|UBX - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan unitybiotechnology.com|UBX - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Unity Biotechnology
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:unitybiotechnology.com UBX
For Unity Biotechnology (UBX), the fundamental P/S ratio reflects the market valuation of senolytic molecule potential relative to current revenue, which is critical while awaiting clinical trial results and maintaining a strict resource-saving regime. This ratio is calculated as market capitalization divided by annual sales volume, allowing investors to assess the premium paid for future business growth compared to actual cash flows.
Pesaing Unity Biotechnology
Kapitalisasi marang volume dodolan TEM|Multiplikator P/S QGEN (Qiagen)|Ionis Pharmaceuticals, Inc. (IONS) - Rega marang dodolan|Repligen Corp. - Multiplikator P/S|Avidity Corp (RNA) - Kapitalisasi marang pendapatan|CRSP: Multiplikator P/S|genedx.com - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Ultragenyx|Rasio kapitalisasi marang pendapatan BEAM (Beam Therapeutics Inc)|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|TWST - Rega marang dodolan|Rasio rega marang pendapatan 10x Genomics, Inc. TXG|intelliatx.com - Rasio rega marang pendapatan|STOK - Rasio rega marang pendapatan|Rega marang dodolan BioLife Solutions Inc|WVE: Multiplikator P/S|Multiplikator rega marang pendapatan Maze Therapeutics Corp MAZE|Kapitalisasi marang pendapatan SION|Rega marang dodolan primemedicine.com PRME|Kapitalisasi marang pendapatan TSHA (Taysha Gene Therapies, Inc.)|Multiplikator P/S uniQure NV (QURE)|Multiplikator P/S MGTX (MeiraGTx PLC)|REGENXBIO Corp - Rasio rega marang pendapatan|SLDB: Kapitalisasi marang pendapatan|OCGN (ocugen.com) - Rasio kapitalisasi marang pendapatan|PACB: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNTC|Rasio rega marang pendapatan Design Pharma|Rasio kapitalisasi marang pendapatan RCKT (Rocket Corp)|Multiplikator P/S FDMT|Multiplikator P/S lexeotx.com (LXEO)|Korro Bio - Kapitalisasi marang pendapatan|Multiplikator P/S Editas Medicine Inc EDIT|SLN - Rasio rega marang pendapatan|PRQR (ProQR Therapeutics N.V.) - Rasio kapitalisasi marang pendapatan|CDXS: Multiplikator P/S|SGMO - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan NAUT|MGX (Metagenomi Inc.) - Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan DTIL (Precision BioSciences, Inc.)|GBIO - Rega marang dodolan|Boundless Bio, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan XCUR|Celsion Corporation - Multiplikator P/S|PHIO: Rasio rega marang pendapatan|MBIO: Multiplikator P/S|RNAZ - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Bionano Genomics Inc.|Rega marang dodolan adnas.com APDN|Kapitalisasi marang pendapatan BLUE (bluebird bio)|Kapitalisasi marang volume dodolan IPA|Multiplikator P/S OMGA (Omega)|Singular Genomics Corp (OMIC) - Rega marang dodolan|Regulus Therapeutics - Multiplikator P/S|syros.com (SYRS) - Kapitalisasi marang pendapatan|TBIO: Multiplikator P/S|TRACON Pharmaceuticals Inc. - Rasio kapitalisasi pasar marang pendapatan
